<DOC>
	<DOC>NCT02929407</DOC>
	<brief_summary>The purpose of this trial is to investigate safety, tolerability, pharmacodynamics, and pharmacokinetics after intravenous administration of FE 204205 in patients with cirrhotic portal hypertension.</brief_summary>
	<brief_title>A Study to Investigate the Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Portal</mesh_term>
	<criteria>1865 years of age Verified cirrhotic portal hypertension Coexisting disease e.g. significant organ failure and decompensated cirrhosis Type 1 hepatorenal syndrome Acuteonchronic liver failure Hepatic encephalopathy â‰¥grade 2 Hepatocellular carcinoma History of underlying chronic heart disease Use of vasopressin or terlipressin within 7 days prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>